Fennec Pharmaceuticals (FENC)

• Market cap: $164M
• 1 day: 2.57%
• 5 days: -1.16%
• 1 month: 29.09%
• 3 months: 14.31%
• 6 months: -8.41%
• Year to date: -46.13%
• 1 year: -42.29%
• 5 years: 1.35%
• 10 years: -50.08%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Employees: 29

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 4 (+2) [Q3]

56% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 16

1.64% more ownership

Funds ownership: 52.94% [Q2] → 54.57% (+1.64%) [Q3]

2% less funds holding

Funds holding: 64 [Q2] → 63 (-1) [Q3]

11% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 9

16% less capital invested

Capital invested by funds: $88.4M [Q2] → $74.7M (-$13.7M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $13 117% upside
• Avg. target: $13 117% upside
• High target: $13 117% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 121 / 308 met price target

117% upside $13

Buy Reiterated

17 Dec 2024